Clinicopathological Significance of SMAD4 Expression in Breast Cancer

Journal of Breast Disease Pub Date : 2019-12-31 DOI:10.14449/jbd.2019.7.2.52

J. Woo, M. Chung, S. Paik

{"title":"Clinicopathological Significance of SMAD4 Expression in Breast Cancer","authors":"J. Woo, M. Chung, S. Paik","doi":"10.14449/jbd.2019.7.2.52","DOIUrl":null,"url":null,"abstract":"Purpose: SMAD4 is a member of the SMAD family and acts as a central mediator of transforming growth factor beta signaling. Little is known about SMAD4 expression and its prognostic significance in breast cancer. We evaluated the clinicopathological and prognostic significance of SMAD4 expression in breast cancer. Methods: Two hundred and fifty-five patients with invasive ductal carcinoma of the breast from 2000 to 2008 were retrospectively analyzed. We investigated SMAD4 expression using a tissue microarray-based immunohistochemical assay and evaluated the association between SMAD4 and prognosis of breast cancer. Results: High SMAD4 expression was positively associated with early stage (p=0.009), estrogen receptor positivity (p=0.026), and human epidermal growth factor receptor 2 negativity (p=0.001). A significant difference in overall survival (OS) was associated with high SMAD4 expression in patients with T1 stage tumors (hazard ratio: 0.459, p=0.024). Conclusion: High SMAD4 expression was correlated with several favorable prognostic factors and was associated with favorable OS in T1 stage breast cancer. SMAD4 in breast cancer has potential prognostic significance, and further investigations and understanding about SMAD4 expression are needed.","PeriodicalId":245382,"journal":{"name":"Journal of Breast Disease","volume":"84 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Breast Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14449/jbd.2019.7.2.52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

Purpose: SMAD4 is a member of the SMAD family and acts as a central mediator of transforming growth factor beta signaling. Little is known about SMAD4 expression and its prognostic significance in breast cancer. We evaluated the clinicopathological and prognostic significance of SMAD4 expression in breast cancer. Methods: Two hundred and fifty-five patients with invasive ductal carcinoma of the breast from 2000 to 2008 were retrospectively analyzed. We investigated SMAD4 expression using a tissue microarray-based immunohistochemical assay and evaluated the association between SMAD4 and prognosis of breast cancer. Results: High SMAD4 expression was positively associated with early stage (p=0.009), estrogen receptor positivity (p=0.026), and human epidermal growth factor receptor 2 negativity (p=0.001). A significant difference in overall survival (OS) was associated with high SMAD4 expression in patients with T1 stage tumors (hazard ratio: 0.459, p=0.024). Conclusion: High SMAD4 expression was correlated with several favorable prognostic factors and was associated with favorable OS in T1 stage breast cancer. SMAD4 in breast cancer has potential prognostic significance, and further investigations and understanding about SMAD4 expression are needed.

查看原文本刊更多论文

乳腺癌中SMAD4表达的临床病理意义

目的:SMAD4是SMAD家族的一员，是转化生长因子β信号的中心介质。SMAD4在乳腺癌中的表达及其预后意义尚不清楚。我们评估了乳腺癌中SMAD4表达的临床病理和预后意义。方法:对2000 ~ 2008年255例乳腺浸润性导管癌患者的临床资料进行回顾性分析。我们使用基于组织微阵列的免疫组化方法研究了SMAD4的表达，并评估了SMAD4与乳腺癌预后之间的关系。结果:SMAD4高表达与早期(p=0.009)、雌激素受体阳性(p=0.026)、人表皮生长因子受体2阴性(p=0.001)呈正相关。T1期肿瘤患者中SMAD4高表达与总生存期(OS)的显著差异相关(风险比:0.459,p=0.024)。结论:SMAD4高表达与T1期乳腺癌的多个有利预后因素相关，并与良好的生存期相关。SMAD4在乳腺癌中具有潜在的预后意义，需要进一步研究和了解SMAD4的表达。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Breast Disease

自引率

0.00%

发文量